Pinned straw:
Inoviq announced today that their process to isolate brain-derived exosomes from a blood sample can be used to detect Parkinson's disease. In July they said they had similar success isolating markers for Alzheimers.
The process increases bio-markers by 5 to 8 times when compared with unprocessed blood, which implies diseases might be detected earlier.
Its great news. yet 'another shot on goal'......to quote all the IIQ management.
But when will these shots be taken?!
I'm getting a bit impatient with IIQ. They always seem to have one product about to get into market...and then BAM....another new product is announced that is likely 3-5 years away.
Lets hope David Williams can speed up the commercial develpment of the SubB2M products......
I think the interesting thing here is the shift of focus to becoming a platform technology rather than the earlier development of specific tests. David Williams is clearly looking for a buyout or equity stake / licensing collaboration.
These slides from the Investor presentation show recent deals in the same field.
